“The immune system is associated with almost every disease, making our technology important for identifying, diagnosing and treating diseases, from cancer to auto-immune disorders,” Solomon said in a statement. The expansion into functional genothm will help our partners address their most pressing questions in developing therapy and ultimately improve the lives of many patients.”
Immunai’s immune records can assist in the discovery of biomarker by detecting changes in cell type and cell expression. For example, the Immunai team described CAR-Natural Killer T (DISABILITY) as a cell transplant therapy product developed at Baylor University School of Medicine for use in patients with neuroblastoma. Baylor and Immunai researchers have identified a gene that is likely involved in the destruction of car-people’s tumor cells and are working to confirm that. In addition, Immunai said it is working with commercial partners to develop cell therapy candidates for dense tumors.
Voloch said Immunai is working with five of the world’s largest pharmaceutical companies alongside stanford, Harvard, Memorial Sloan Kettering and the University of Pennsylvania. “We have developed a new platform to re-program immunity by harnessing AMICA, our exclusive comprehensive single cell immunity database, with advanced conversion algorithms and multi-task learning,” he added. “Vertical integrated functional learning genes and AI capabilities allow us to prioritize and validate goals more accurately.”
Immunai has 70 employees based in New York City and offices in San Francisco and Tel Aviv. The A-series round announced today is led by the Schusterman Foundation, Duquesne Family, Catalio Capital Management and Dexcel Pharma. Current investors Viola Venture and TLV Partners also participated, raising Immunai’s current total raised $80 million.